Aligos Therapeutics, Inc. (ALGS) SEC filings

ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3010% below fair value

$1.98−0.18 (-8.33%)

Close on Nov 12, 2026Market cap $24.73MP/E –Yield –

SEC filings

40 of Aligos Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 6, 2026	SEC EDGAR
Current report	8-K	Nov 6, 2026	Nov 6, 2026	SEC EDGAR
Current report	8-K	Sep 10, 2026	Sep 15, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 25, 2026	Jun 26, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 25, 2026	Apr 29, 2026	SEC EDGAR
Current report	8-K	Apr 16, 2026	Apr 21, 2026	SEC EDGAR
Current report	8-K	Apr 14, 2026	Apr 14, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 5, 2026	SEC EDGAR
Current report	8-K	Mar 5, 2026	Mar 5, 2026	SEC EDGAR
Current report	8-K	Jan 29, 2026	Feb 4, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Aug 6, 2025	Aug 6, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 6, 2025	SEC EDGAR
Current report	8-K	Jun 25, 2025	Jun 26, 2025	SEC EDGAR
Current report	8-K	May 6, 2025	May 6, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 6, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 25, 2025	Apr 28, 2025	SEC EDGAR
Current report	8-K	Mar 10, 2025	Mar 10, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 10, 2025	SEC EDGAR
Current report	8-K	Feb 11, 2025	Feb 12, 2025	SEC EDGAR
Current report	8-K	Jan 30, 2025	Feb 3, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2024	Nov 6, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 6, 2024	SEC EDGAR
Current report	8-K	Sep 3, 2024	Sep 5, 2024	SEC EDGAR
Current report	8-K	Aug 14, 2024	Aug 19, 2024	SEC EDGAR
Current report	8-K	Aug 7, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Aug 6, 2024	Aug 6, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 6, 2024	SEC EDGAR
Current report	8-K	Jun 27, 2024	Jun 28, 2024	SEC EDGAR
Current report	8-K	May 29, 2024	May 31, 2024	SEC EDGAR
Current report	8-K	May 21, 2024	May 22, 2024	SEC EDGAR
Current report	8-K	May 9, 2024	May 15, 2024	SEC EDGAR
Current report	8-K	May 7, 2024	May 7, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 7, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 27, 2024	Apr 29, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Aligos Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-25 reverse split on Aug 19, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALGS.

Compare: ALGS vs TSHA · ALGS vs ELOX · ALGS vs PRME · ALGS vs MOLN · ALGS vs OCGN

Company	Revenue	Growth
ALGS	$5.83M	+122.2%
TSHA	$5.49M	-13.1%
ELOX	–	–
PRME	–	–
MOLN	–	–
OCGN	–	–

Company

Next earnings (est.): Mar 4, 2027, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 82
Held by institutions: 18.4%
Auditor: Ernst & Young LLP
SEC CIK: 1799448

Advertisement
300 × 250

See a number that looks wrong?